irbesartan

GPTKB entity

Statements (54)
Predicate Object
gptkbp:instanceOf gptkb:drug
angiotensin II receptor blocker
gptkbp:approvalYear 1997
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode C09CA04
gptkbp:availableOn gptkb:tablet
gptkbp:brand gptkb:Aprovel
Avapro
Irovel
Karvea
gptkbp:CASNumber 138402-11-6
gptkbp:category gptkb:sartan
antihypertensive agent
gptkbp:chemicalFormula C25H28N6O
gptkbp:contraindication pregnancy
bilateral renal artery stenosis
gptkbp:developedBy gptkb:Sanofi
gptkbp:drugClass angiotensin receptor blocker
gptkbp:eliminationHalfLife 11-15 hours
gptkbp:excretion urine
bile
gptkbp:firstSynthesized 1990s
https://www.w3.org/2000/01/rdf-schema#label irbesartan
gptkbp:interactsWith gptkb:NSAIDs
gptkb:aliskiren
lithium
potassium-sparing diuretics
gptkbp:legalStatus prescription only
off-patent
gptkbp:mechanismOfAction gptkb:angiotensin_II_receptor_antagonist
gptkbp:metabolism liver
gptkbp:molecularWeight 428.53 g/mol
gptkbp:notRecommendedFor pregnant women
breastfeeding women
gptkbp:pregnancyCategory D (US)
gptkbp:prescribes adults
children over 6 years (in some countries)
gptkbp:proteinBinding 90%
gptkbp:riskFactor renal impairment
hyperkalemia
angioedema
gptkbp:routeOfAdministration oral
gptkbp:sideEffect dizziness
fatigue
hypotension
hyperkalemia
gptkbp:usedFor hypertension
diabetic nephropathy
gptkbp:WHOModelListOfEssentialMedicines true
gptkbp:bfsParent gptkb:Aprovel
gptkb:angiotensin_II_receptor_antagonist
gptkb:AT1_receptor
gptkb:angiotensin_receptor_blockers
gptkbp:bfsLayer 7